Overall, the therapeutic effects of these pharmacological p53-activators require the existence of wild-type p53, as they are ineffective in tumors with mutant p53. Although most of the published studies focus on MDM2 inhibition-induced tumor cell apoptosis, a couple of recent observations demonstrated that Nultin-3 also regulates host immune response by modulating the immunological function of dendritic cells or other antigen presenting cells [136,137], making it a potential candidate of immunotherapy adjuvant. This evidence concerns the gene TP53 and neoplasm.